NCT01744730View on ClinicalTrials.gov

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Bacterial InfectionsObesity
Interventions
DRUG

Clindamycin

Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.

Trial Locations (4)

40202

University of Louisville, Louisville

48109

Akron Children's Hospital, Akron

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

64108

Children's Mercy Hospital, Kansas City

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

Phillip Brian Smith

OTHER

NCT01744730 - Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile | Biotech Hunter | Biotech Hunter